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Background: Cardiac amyloidosis is an infiltrative cardiomyopathy that is challenging to diagnose and carries a poor prognosis. Early 
recognition and treatment can improve outcome. We hypothesized that the novel biomarkers Hepatocyte Growth Factor (HGF), Galectin-3 
(GAL-3), Interleukin-6 (IL-6), and Vascular Endothelial Growth Factor (VEGF) would be elevated in cardiac amyloidosis and may be able to 
discriminate from non-cardiac systemic amyloidosis or other cardiomyopathies with similar clinical or morphologic characteristics.
methods: Patients were selected according to the following groups: 1) cardiac amyloidosis (systemic amyloidosis + positive biopsy or 
MRI), 2) non-cardiac systemic amyloidosis; 3) LVH (LV mass index (LVMI) >115 g/m2 in men and >95 g/m2 in women with relative wall 
thickness (RWT) >0.44); and 4) systolic HF (LVEF ≤30% and NYHA class ≥III). Gal-3, HGF, IL-6, and VEGF were measured in stored 
plasma samples.
results: HGF was markedly elevated in patients with cardiac amyloidosis compared to the other groups, including those with non-cardiac 
systemic amyloidosis (Table 1). Gal-3 was elevated in patients with amyloidosis with or without cardiac involvement compared to LVH and 
systolic HF. There was no difference in IL-6 or VEGF between groups.
conclusion:  GAL-3 is elevated in amyloidosis regardless of cardiac involvement. HGF is a specific marker that distinguishes cardiac 
amyloidosis from other cardiomyopathies and may discern cardiac involvement in systemic amyloidosis. 
